
SANTA CRUZ BIOTECHNOLOGY, INC.

p-PTEN (Ser 370): sc-101787



BACKGROUND

As human tumors progress to advanced stages, one genetic alteration that occurs at high frequency is a loss of heterozygosity (LOH) at chromosome 10q23. Mapping of homozygous deletions on this chromosome led to the isolation of the PTEN gene, also designated MMAC1 (for mutated in multiple advanced cancers) and TEP1. This candidate tumor suppressor gene exhibits a high frequency of mutations in human glioblastomas and is also mutated in other cancers, including sporadic brain, breast, kidney and prostate cancers. PTEN has been associated with Cowden disease, an autosomal dominant cancer predisposition syndrome. The PTEN gene product is a putative protein tyrosine phosphatase that is localized to the cytoplasm, and it shares extensive homology with the cytoskeletal proteins tensin and auxilin. Gene transfer studies have indicated that the phosphatase domain of PTEN is essential for growth suppression of glioma cells. PTEN contains five major phosphorylation sites and these are all located in the C-terminal 50 amino acid tail region (Ser 370, Ser 380, Thr 382, Thr 383 and Ser 385) and have been implicated in controlling PTEN activity.

REFERENCES

- Bigner, S.H., et al. 1988. Specific chromosomal abnormalities in malignant human gliomas. Cancer. Res. 48: 405-411.
- James, C.D., et al. 1988. Clonal genomic alterations in glioma malignancy stages. Cancer. Res. 48: 5546-5551.
- Steck, P.A., et al. 1997. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15: 356-362.
- Li, J., et al. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
- Liaw, D., et al. 1997. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16: 64-67.
- Nelen, M.R., et al. 1997. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum. Mol. Genet. 6: 1383-1387.
- 7. Furnari, F.B., et al. 1997. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc. Natl. Acad. Sci. USA 94: 12479-12484.

CHROMOSOMAL LOCATION

Genetic locus: PTEN (human) mapping to 10q23.31; Pten (mouse) mapping to 19 C1.

SOURCE

p-PTEN (Ser 370) is a rabbit polyclonal antibody raised against a short amino acid sequence containing phosphorylated Ser 370 of PTEN of human origin.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PRODUCT

Each vial contains 100 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

p-PTEN (Ser 370) is recommended for detection of Ser 370 phosphorylated PTEN of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1–2 μ g per 100–500 μ g of total protein (1 ml of cell lysate)], immunofluorescence and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500).

Suitable for use as control antibody for PTEN siRNA (h): sc-29459, PTEN siRNA (h2): sc-44272, PTEN siRNA (m): sc-36326, PTEN siRNA (m2): sc-44324 and PTEN siRNA (r): sc-61873.


Molecular Weight of p-PTEN: 55 kDa.


Positive Controls: human breast carcinoma tissue, vanadate-treated A-431 whole cell lysate or Calyculin A-treated HT-29 whole cell lysate.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-rabbit IgG-HRP: sc-2004 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible goat anti-rabbit IgG-HRP: sc-2030 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto B Blocking Reagent: sc-2335 (use 50 mM NaF, sc-24988, as diluent) and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use goat anti-rabbit IgG-FITC: sc-2012 (dilution range: 1:100-1:400) or goat anti-rabbit IgG-FIT: sc-2780 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941. 4) Immunohistochemistry: use ImmunoCruz™: sc-2051 or ABC: sc-2018 rabbit IgG Staining Systems.

DATA





p-PTEN (Ser 370): sc-101787. Western blot analysis of phosphorylated PTEN expression in untreated (**A**) and vanadate-treated (**B**) A-431 whole cell lysates.

p-PTEN (Ser 370): sc-101787. Immunoperoxidase staining of formalin-fixed, paraffin-embedded human breast carcinoma tissue showing cytoplasmic staining.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.